Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease
The FDA has approved the subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease after induction therapy via IV administration. The approval was based on the results of a phase 3 clinical trial, VISIBLE 2, which showed that patients who received SC vedolizumab achieved higher rates of clinical…